Wyss Institute for Biologically Inspired Engineering at Harvard University
The Wyss Institute uses biological design principles to develop innovative solutions that transform medicine and create a sustainable world. It leverages insights from nature to develop disruptive technologies across various fields, translating them into products and therapies through startups and corporate alliances. The institute focuses on multiple areas including therapeutics, diagnostics, organ engineering, synthetic biology, and more, with a strong emphasis on collaboration, innovation, and commercialization.
Industries
Nr. of Employees
medium (51-250)
Wyss Institute for Biologically Inspired Engineering at Harvard University
Boston, Massachusetts, United States, North America
Products
Organ chip platform
Microfluidic chips that recapitulate human organ microarchitecture and function for drug testing, disease modeling, and linked multi-organ studies.
DNA nanostructure delivery and vaccine platform
Programmable DNA nanostructures for nanoscale control of antigen/adjuvant spacing and co-delivery of therapeutic cargos to modulate immune responses.
Electrochemical multiplexed sensing platform
Portable electrochemical sensor system enabling multiplexed, rapid detection of diverse biomarkers with antifouling surface treatments for complex samples.
Cell-free on-demand biomolecule production platform
Freeze-dried cell-free production methods for ambient-stable, on-site synthesis of vaccines, peptides, and reagent proteins without cold-chain dependence.
Mechanically-activated clot-targeting nanotherapeutic
Theranostic nanocarriers engineered to activate in regions of high shear or mechanical stress to preferentially target and dissolve vascular occlusions.
Liquid-infused anti-biofouling coating for medical devices
Surface technology designed to minimize clotting and biofouling on medical devices and implants to improve device longevity and reduce complications.
Organ chip platform
Microfluidic chips that recapitulate human organ microarchitecture and function for drug testing, disease modeling, and linked multi-organ studies.
DNA nanostructure delivery and vaccine platform
Programmable DNA nanostructures for nanoscale control of antigen/adjuvant spacing and co-delivery of therapeutic cargos to modulate immune responses.
Electrochemical multiplexed sensing platform
Portable electrochemical sensor system enabling multiplexed, rapid detection of diverse biomarkers with antifouling surface treatments for complex samples.
Cell-free on-demand biomolecule production platform
Freeze-dried cell-free production methods for ambient-stable, on-site synthesis of vaccines, peptides, and reagent proteins without cold-chain dependence.
Mechanically-activated clot-targeting nanotherapeutic
Theranostic nanocarriers engineered to activate in regions of high shear or mechanical stress to preferentially target and dissolve vascular occlusions.
Liquid-infused anti-biofouling coating for medical devices
Surface technology designed to minimize clotting and biofouling on medical devices and implants to improve device longevity and reduce complications.
Services
Collaborative program partnering with clinicians and industry to identify unmet diagnostic needs, support biomarker discovery, and advance test prototypes toward clinical validation.
Pre-competitive laboratory capabilities and clinical collaborations to identify and validate biomarkers and bridge discovery to market-ready diagnostic assays and instruments.
Pre-competitive research sponsorship, non-exclusive licensing, and co-development opportunities to advance brain-targeting delivery approaches for central nervous system therapeutics.
Collaborative program partnering with clinicians and industry to identify unmet diagnostic needs, support biomarker discovery, and advance test prototypes toward clinical validation.
Pre-competitive laboratory capabilities and clinical collaborations to identify and validate biomarkers and bridge discovery to market-ready diagnostic assays and instruments.
Pre-competitive research sponsorship, non-exclusive licensing, and co-development opportunities to advance brain-targeting delivery approaches for central nervous system therapeutics.
Expertise Areas
- Organ-on-chip systems and human-relevant in vitro modeling
- Tissue engineering and multiscale vascularized tissue fabrication
- DNA nanotechnology and nanoscale delivery systems
- Synthetic biology and genome engineering for therapeutics and manufacturing
Key Technologies
- Organ-on-chip microfluidics
- DNA origami and programmable DNA nanostructures
- DNA nanoswitches for single-molecule proteomics
- Extracellular vesicle analysis
News & Updates
News about Natalie Artzi's appointment as Associate Institute Director at Wyss Institute.
News about Kwasi Adu-Berchie on reimagining infectious disease treatment.
An article discussing the impact of CRISPR technology.
News about Natalie Artzi's appointment as Associate Institute Director at Wyss Institute.
News about Kwasi Adu-Berchie on reimagining infectious disease treatment.
An article discussing the impact of CRISPR technology.